Evotec SE (EVO) Free Cash Flow (2009 - 2026)
Evotec SE (EVO) reported Free Cash Flow of $289.17 for Q1 2026, up 102.02% on a YoY basis from $143.14 in Q1 2025, and up 100.0% sequentially from -$95.1 million in Q4 2025.
Evotec SE (EVO) Free Cash Flow (2009 - 2026) Analysis & Trends
Evotec SE (EVO) has 9 years of Free Cash Flow data on file, last reported at $289.17 in Q1 2026.
- For the quarter ending Q1 2026, Free Cash Flow rose 102.02% year-over-year to $289.17; the trailing twelve-month figure through Mar 2026 stood at -$95.1 million (up 10.32% YoY), and the FY2025 full-year result was -$95.1 million, up 10.31% from the prior year.
- Free Cash Flow improved to $289.17 in Q1 2026, from -$95.1 million in the prior quarter.
- In the past five years, Free Cash Flow ranged from a high of $24.9 million in Q4 2022 to a low of -$190.5 million in Q4 2023.
- A 5-year average of -$21.6 million and a median of -$8625.7 in 2024 frame the typical range for Free Cash Flow.
- Peak annual rise in Free Cash Flow reached 255676.65% in 2022, while the deepest fall reached 2943.9% in 2022.
- Tracing EVO's Free Cash Flow over 5 years: stood at $24.9 million in 2022, then sank by 865.92% to -$190.5 million in 2023, then soared by 44.3% to -$106.1 million in 2024, then advanced by 10.36% to -$95.1 million in 2025, then jumped by 100.0% to $289.17 in 2026.
- Business Quant data shows EVO's Free Cash Flow at $289.17 in Q1 2026, -$95.1 million in Q4 2025, and -$55352.4 in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | -208.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 291.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -373.37 Mn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 363.70 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 348.40 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 144.40 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | -38.00 Mn |
| 10 | Evotec SE | 351.60 Mn | 351.08 Mn | - | 289.17 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 289.17 |
| Mar 31, 2026 | 289.17 |
| Dec 31, 2025 | -95.11 Mn |
| Dec 31, 2025 | -95.11 Mn |
| Sep 30, 2025 | -55,352.42 |
| Sep 30, 2025 | -55,352.42 |
| Jun 30, 2025 | 52,064.49 |
| Jun 30, 2025 | 52,064.49 |
| Mar 31, 2025 | -14,316.15 |
| Mar 31, 2025 | -14,316.15 |
| Dec 31, 2024 | -106.11 Mn |
| Dec 31, 2024 | -106.11 Mn |
| Sep 30, 2024 | 76,188.98 |
| Sep 30, 2024 | 76,188.98 |
| Jun 30, 2024 | -16,334.23 |
| Jun 30, 2024 | -16,334.23 |
| Mar 31, 2024 | -8,625.71 |
| Mar 31, 2024 | -8,625.71 |
| Dec 31, 2023 | -190.49 Mn |
| Dec 31, 2023 | -190.49 Mn |